FTSE 100 news / Companies and sectors / Haleon / 21 October 2026

Haleon (HLN): news on Wednesday 21 October 2026

+5.5 positive

Coverage was mostly positive, with UBS pointing to possible earnings upside from an early flu season and Goldman keeping its Buy rating. Oral health strength and an Excedrin push added support, though valuation remained a talking point.

What drove it

analyst ratings
flu season earnings
oral health strength

The 4 stories

Each headline's own score, strongest first. Links go to the publisher.

+7.0 UBS says early flu pick-up could lift 2027 earnings at Reckitt and Haleon Proactive financial news
UBS says early flu season could lift Haleon's 2027 earnings.}, {
+6.3 Haleon schedules Toronto Health House as Goldman keeps Buy for Haleon stock - ad-hoc-news.de ad-hoc-news.de
Goldman maintains Buy rating; company event scheduled in Toronto.
+5.7 FTSE 100 Haleon (LSE:HLN) Leans on Oral Health Strength Kalkine Media
Oral health segment strength highlighted as supportive for the business.
+3.0 Haleon (LSE:HLN) Launches Excedrin Push With Valuation Still In Focus Simply Wall Street
Excedrin marketing push, though valuation remains a question.

Haleon: every day · Pharma and healthcare on 21 October 2026 · FTSE 100 overview for the day